You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 11, 2025

Saptalis Pharms Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Saptalis Pharms
International Patents:5
US Patents:1
Tradenames:7
Ingredients:6
NDAs:7

Drugs and US Patents for Saptalis Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Saptalis Pharms GLYCOPYRROLATE glycopyrrolate SOLUTION;ORAL 216297-001 Oct 7, 2024 AA RX No No ⤷  Try for Free ⤷  Try for Free
Saptalis Pharms VOSOL HC acetic acid, glacial; hydrocortisone SOLUTION/DROPS;OTIC 012770-001 Approved Prior to Jan 1, 1982 AT RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Saptalis Pharms CYCLOSPORINE cyclosporine EMULSION;OPHTHALMIC 211943-001 Jul 5, 2024 AB RX No No ⤷  Try for Free ⤷  Try for Free
Saptalis Pharms CLOBETASOL PROPIONATE clobetasol propionate SOLUTION;TOPICAL 211494-001 Oct 2, 2019 AT RX No No ⤷  Try for Free ⤷  Try for Free
Saptalis Pharms METRONIDAZOLE metronidazole GEL;VAGINAL 216750-001 Dec 31, 2024 AB RX No No ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Saptalis Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1412357 PA2008013,C1412357 Lithuania ⤷  Try for Free PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716
1506211 PA2014026,C1506211 Lithuania ⤷  Try for Free PRODUCT NAME: DAPAGLIFLOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
2435024 2190014-7 Sweden ⤷  Try for Free PRODUCT NAME: A COMBINATION OF FORMOTEROL INCLUDING ANY PHARMACEUUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, GLYCOPYRROLATE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, AND BUDESONIDE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALT, ESTERS ORSOLVATES THEREOF; REG. NO/DATE: EU/1/20/1498 20201210
1412357 C 2008 016 Romania ⤷  Try for Free PRODUCT NAME: SITAGLIPTIN OPTIONAL SUB FORMA DE SARE ACCEPTABILAFARMACEUTIC IN SPECIAL MONOFOSFAT + METFORMIN OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC IN SPECIALCLORHIDRAT; NATIONAL AUTHORISATION NUMBER: RO EU/1/08/455/001 - RO EU/1/08/455/014; DATE OF NATIONAL AUTHORISATION: 20080716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): CH 58450 01, CH 58450 02, CH 58450 03; DATE OF FIRST AUTHORISATION IN EEA: 20080408
1506211 SPC/GB14/050 United Kingdom ⤷  Try for Free PRODUCT NAME: A COMBINATION OF DAPAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND METFORMIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/13/900 20140121
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Saptalis Pharms – Market Position, Strengths & Strategic Insights

In the dynamic and competitive pharmaceutical industry, understanding a company's market position and strategic advantages is crucial for success. Saptalis Pharmaceuticals, a rapidly growing player in the field, has carved out a unique niche for itself through innovative product development and strategic partnerships. This comprehensive analysis delves into Saptalis' market position, strengths, and key insights that drive its competitive edge.

The Rise of Saptalis Pharmaceuticals

Founded in 2015, Saptalis Pharmaceuticals has quickly established itself as a formidable contender in the pharmaceutical landscape. The company specializes in the development, manufacturing, and commercialization of niche generic and innovative specialty products, with a particular focus on liquid and semi-solid dosage forms[3].

A Focused Approach to Product Development

Saptalis has strategically positioned itself by concentrating on non-sterile and sterile liquid and semi-solid dosage forms. This targeted approach allows the company to excel in a specific area of expertise, setting it apart from broader-focused competitors[3].

"Saptalis takes pride in its highly experienced team of scientists, state-of-the-art R&D laboratories, and the FDA inspected manufacturing facilities equipped and qualified to meet its growing commercial production needs."[3]

Market Position and Product Portfolio

Saptalis has rapidly expanded its market presence through a combination of strategic product launches and acquisitions. Let's examine some key aspects of their market position:

Diverse Product Range

The company's product portfolio includes both generic and innovative pharmaceutical products, developed through ANDA and 505(b)(2) regulatory pathways[3]. This diversification allows Saptalis to cater to various market segments and reduce dependency on a single product line.

Strategic Acquisitions

In a significant move to strengthen its market position, Saptalis acquired a portfolio of 15 ANDAs for non-sterile liquid and semi-solid products, along with an NDA for Acetic Acid/Hydrocortisone Otic Solution. This acquisition alone represented a market value of approximately $115 million, according to IQVIA data[1].

Focus on High-Value Markets

Saptalis has shown a keen interest in entering markets with limited generic competition. For instance, their acquisition of 18 ANDAs for sterile ophthalmic solutions and ointments targets a market valued at approximately $160 million, with many products facing limited or no competition in the US market[1].

Strengths and Competitive Advantages

Saptalis' rapid growth and market penetration can be attributed to several key strengths:

1. Specialized Expertise

The company's focus on liquid and semi-solid dosage forms has allowed it to develop deep expertise in these areas, enabling the creation of complex formulations that many competitors might find challenging[3].

2. State-of-the-Art Facilities

Saptalis operates a 10,000 sq. ft. R&D facility staffed by highly qualified and experienced pharmaceutical formulation scientists and analytical chemists[10]. This investment in research infrastructure positions the company to drive innovation and maintain a competitive edge.

3. Strategic Partnerships

Saptalis has demonstrated a knack for forming beneficial partnerships. For example, its collaboration with Appili Therapeutics for the development and commercialization of ATI-1501 showcases the company's ability to leverage external expertise and expand its market reach[2].

4. First-to-File Advantage

In several instances, Saptalis has been the first generic company to file ANDAs with paragraph IV certifications, successfully challenging patents of branded products. This strategy has allowed the company to secure valuable 180-day exclusivity periods for certain products[7].

Product Development and Innovation

Saptalis' approach to product development is a cornerstone of its competitive strategy. Let's explore some key aspects:

Focus on Unmet Needs

The company has shown a commitment to addressing unmet medical needs. For instance, its development of a liquid formulation of metformin targets patients who have difficulty swallowing solid dosage forms, particularly geriatric and pediatric populations[7].

Innovative Formulations

Saptalis is actively working on complex formulations, including nanosuspensions and microemulsions[7]. This focus on advanced drug delivery systems positions the company at the forefront of pharmaceutical innovation.

Market Expansion and Growth Strategy

Saptalis' growth strategy encompasses several key elements:

1. Geographic Expansion

The company has shown interest in expanding beyond the US market. Its agreement with Appili Therapeutics for ATI-1501 now includes rights for Europe and Latin America, indicating a push for international growth[2].

2. Portfolio Diversification

By acquiring diverse product portfolios and developing both generic and innovative products, Saptalis is spreading its risk and creating multiple revenue streams[1].

3. Manufacturing Capabilities

Saptalis is investing in expanding its manufacturing capabilities, with plans to transfer acquired products to its Hauppauge, NY facility. This vertical integration can lead to better control over the supply chain and potentially higher profit margins[1].

Challenges and Future Outlook

While Saptalis has shown impressive growth, it faces several challenges:

Intense Competition

The pharmaceutical industry is highly competitive, with both established players and new entrants vying for market share. Saptalis must continue to innovate and differentiate its offerings to maintain its growth trajectory.

Regulatory Hurdles

As with all pharmaceutical companies, Saptalis faces the ongoing challenge of navigating complex regulatory environments. The company's success will depend on its ability to efficiently shepherd products through the approval process.

Scaling Operations

As Saptalis grows, it will need to scale its operations effectively. This includes managing an expanding product portfolio, maintaining quality standards, and potentially entering new geographic markets.

Strategic Insights for Future Growth

Based on the analysis of Saptalis' current position and market trends, several strategic insights emerge:

  1. Continue Focus on Niche Markets: Saptalis' success in targeting markets with limited competition suggests this strategy should remain a priority.

  2. Invest in R&D: To maintain its competitive edge, continued investment in research and development of complex formulations will be crucial.

  3. Expand Strategic Partnerships: Collaborations like the one with Appili Therapeutics can provide access to new technologies and markets.

  4. Leverage First-to-File Strategy: Pursuing first-to-file opportunities for generic products can secure valuable market exclusivity periods.

  5. Explore International Markets: Building on the expansion into Europe and Latin America, Saptalis could consider further international growth to diversify its market presence.

Key Takeaways

  • Saptalis Pharmaceuticals has rapidly established itself as a significant player in the pharmaceutical industry since its founding in 2015.
  • The company's focus on liquid and semi-solid dosage forms has allowed it to develop specialized expertise and target niche markets.
  • Strategic acquisitions and partnerships have played a crucial role in Saptalis' growth and market expansion.
  • The company's commitment to innovation, particularly in complex formulations, positions it well for future growth.
  • Saptalis faces challenges including intense competition and regulatory hurdles but has demonstrated adaptability and strategic acumen.
  • Future success will likely depend on continued focus on niche markets, R&D investment, and strategic partnerships.

FAQs

  1. What is Saptalis Pharmaceuticals' main area of focus? Saptalis specializes in the development, manufacturing, and commercialization of niche generic and innovative specialty products, with a particular emphasis on liquid and semi-solid dosage forms.

  2. How has Saptalis expanded its product portfolio? Saptalis has grown its portfolio through a combination of in-house development, strategic acquisitions, and partnerships with other pharmaceutical companies.

  3. What competitive advantages does Saptalis have in the pharmaceutical market? Key advantages include specialized expertise in liquid and semi-solid dosage forms, state-of-the-art R&D facilities, strategic partnerships, and a track record of successful first-to-file generic applications.

  4. How is Saptalis addressing unmet medical needs? The company focuses on developing products for underserved patient populations, such as liquid formulations for those who have difficulty swallowing solid dosage forms.

  5. What are some potential future growth areas for Saptalis? Future growth opportunities may include further expansion into international markets, continued development of complex formulations, and targeting additional niche markets with limited competition.

Sources cited:

  1. http://www.saptalis.com/news
  2. https://appilitherapeutics.com/2022/02/08/appili-therapeutics-expands-ati-1501-commercial-agreement-with-partner-saptalis-pharmaceuticals/
  3. http://www.saptalis.com/about-saptalis
  4. https://www.prnewswire.com/news-releases/micro-labs-usa-inc-and-saptalis-pharmaceuticals-llc-announce-launch-of-metformin-oral-solution-500-mg5ml-in-two-presentations-118ml-and-473ml-301058587.html
  5. https://www.pharmacompass.com/pharma-services/api-fdf-drug-development/saptalis-pharm

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.